Idelalisib Clinical Trials

4 actively recruiting trials across 2 locations

No change since May 2026

Pipeline

Phase 2: 1Phase 3: 2Phase 4: 1

Top Sponsors

Oslo University Hospital1
Eli Lilly and Company1
Dizal (Jiangsu) Pharmaceutical Co., Ltd.1
BeOne Medicines1

Indications

Cancer4
Chronic Lymphocytic Leukemia2
CLL1
Lymphoma, Small Lymphocytic1
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma1

Other2 trials

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Phase 3

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

Mobile, Alabama1 trial

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Mitchell Cancer Institute

Phase 4

Jonesboro, Arkansas1 trial

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

St Bernards Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.